Company profile
Inventiva S.A.
NASDAQ:IVABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Lanifibranor | phase3 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04849728 | phase3 | active_not_recruiting | 2021-08-19 | 2027-09-30 | Inventiva Pharma | A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) |
| NCT03370653 | phase2 | completed | 2017-12-30 | 2019-09-24 | Inventiva Pharma | A Study in MPS VI to Assess Safety and Efficacy of Odiparcil |
| NCT03866369 | phase1 | completed | 2019-01-17 | 2019-08-27 | Inventiva Pharma | Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose |
| NCT03008070 | phase2 | completed | 2017-02-07 | 2020-02-20 | Inventiva Pharma | Phase 2b Study in NASH to Assess IVA337 |
| NCT05232071 | phase2 | completed | 2022-06-29 | 2024-03-30 | Inventiva Pharma | Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus |
FDA applications (0)
No records yet.